Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: tony echols who wrote (694)	9/2/1998 10:04:00 AM
From: M.A. Caccavo	Read Replies (1) \| Respond to of 849

I heard this morning the Sloan-Kettering determined the protein associated with prostate cancer. Does this have ANY impact positive or negative on our pathetic friend NMPS?

To: tony echols who wrote (694)	10/6/1998 5:47:00 AM
From: Marty Lee	Respond to of 849

NMP179.. Anybody have a comment on the recent mailing from Matritech on the award they are about to receive? (for the development of NMP179 for use in the diagnosis of cervical cancer) More products, expanding distribution base. Anyone care to speculate how much longer this company will be in the red? What are the company's prospects for profit as the company grows and its NMP technology becomes universally adopted? The probability of success for Matritech is looking better. Ciao for now, Marty